Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Arcellx’s chief medical officer sells shares worth $581,315 By Investing.com
    News

    Arcellx’s chief medical officer sells shares worth $581,315 By Investing.com

    userBy userJanuary 10, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Christopher Heery, the Chief Medical (TASE:) Officer of Arcellx, Inc. (NASDAQ:ACLX), a $3.74 billion market cap biotech company currently trading near $69 per share, recently reported the sale of company shares totaling $581,315. According to InvestingPro analysis, the stock has declined 12.7% over the past week. The transactions were executed over two days, with a sale of 4,230 shares on January 7, 2025, at an average price of $75.53 per share, followed by a sale of 3,553 shares on January 8, 2025, at an average price of $73.69 per share. These sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Heery retains direct ownership of 25,085 shares of Arcellx common stock. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 4.29. Want deeper insights into insider trading patterns and 10+ additional ProTips? Discover more with InvestingPro.

    In other recent news, Arcellx Inc. has seen a series of positive developments, with multiple investment firms maintaining or upgrading their ratings and adjusting their price targets for the company. Stifel, TD Cowen, BofA Securities, and Truist Securities all maintained Buy ratings, highlighting the potential of Arcellx’s anito-cel therapy. The firms cited the therapy’s efficacy, safety profile, and manufacturing capabilities as key factors in their positive assessments.

    Piper Sandler also maintained an Overweight rating on Arcellx, raising the price target following the company’s third-quarter 2024 earnings report. The firm expressed optimism about the upcoming full data release from the iMMagine-1 study for anito-cel at the American Society of Hematology meeting.

    Arcellx’s recent earnings announcement and the anticipation surrounding the iMMagine-1 study data have contributed to the revised price targets. The company’s financial position, with a reported $677 million in cash and equivalents, was also noted by Truist Securities. These recent developments underscore the growing market confidence in Arcellx and its anito-cel therapy.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleInvesting Social Security money in the stock market
    Next Article McDonald’s to close three CosMc’s locations — and open two more
    user
    • Website

    Related Posts

    Want to turn a £20k ISA into a £1k second income overnight? Here’s how

    June 8, 2025

    £10,000 invested in Standard Chartered shares 2 years ago is now worth…

    June 8, 2025

    Over the next 10 years, I think I’ll make the most money in this area of the stock market

    June 8, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d